Do GLP-1 Medications Work During Menopause? Here's What the Research Shows

Many women assume menopause breaks the metabolic rules — and they're not entirely wrong to worry. Menopause (defined as 12 consecutive months without a period) brings a measurable metabolic shift. The SWAN study (Study of Women's Health Across the Nation), which has followed thousands of women through the menopause transition since 1996, found that women gain on average about 1.5 pounds per year during midlife, with fat redistributing toward the abdomen even when total weight stays stable.

The culprit is falling estrogen, which influences where fat is stored, how hungry you feel, and how much lean muscle you keep. Add in sleep disruption from night sweats and the natural age-related decline in muscle mass, and many women find that diets which worked at 35 do nothing at 52.

So when a woman in perimenopause or postmenopause considers a GLP-1 medication, the question is fair: do these drugs still work when your hormones have changed the playing field? The short answer from the research is yes — and in some ways, the menopausal body may be exactly the situation GLP-1s are built for, because they target visceral fat and appetite dysregulation, the two biggest midlife changes. We cover the belly-fat connection in depth in our guide to [GLP-1 and visceral fat in menopause](/blog/glp1-visceral-fat-menopause-belly-fat-guide).

The research consistently shows GLP-1s work well in postmenopausal women. The strongest direct evidence comes from a 2024 retrospective cohort study published in the journal Menopause (the journal of The Menopause Society). Researchers followed postmenopausal women treated with semaglutide and found clinically significant weight loss across the board — and a striking bonus: women who were also using menopausal hormone therapy (HRT) lost roughly 30% more relative body weight, approximately 16% versus 12% of starting weight at 12 months.

Zoom out to the landmark trials and the picture stays positive. In STEP 1 (NEJM 2021), semaglutide 2.4 mg produced an average 14.9% weight loss over 68 weeks, and women — most of mid-life age — lost a greater percentage of body weight than men on average. In SURMOUNT-1 (NEJM 2022), tirzepatide produced up to 20.9% average weight loss at the highest dose, with women again showing numerically larger losses than men in subgroup analyses.

No major trial has found that menopausal status erases the effect of a GLP-1. The medications work on gut hormones, brain appetite circuits, and gastric emptying — pathways that remain fully active after estrogen declines.

Menopause doesn't weaken GLP-1s, but it changes the context they operate in. Estrogen and GLP-1 (glucagon-like peptide-1, a gut hormone that signals fullness) share overlapping appetite pathways in the brain. Animal research suggests estrogen amplifies GLP-1 signaling — one reason scientists believe restoring estrogen through HRT may make semaglutide more effective, as the 2024 Menopause study observed.

Three menopause-specific factors are worth knowing. First, visceral fat: after menopause, fat shifts preferentially to the abdomen, and visceral fat is more metabolically harmful — but it's also the fat GLP-1s reduce most readily. Second, insulin resistance rises after menopause; GLP-1s directly improve insulin sensitivity, which is why they began as diabetes drugs. Third, muscle loss accelerates: women can lose muscle faster in the years around menopause, and rapid weight loss adds to that risk. That's why protein targets and strength training are non-negotiable — see our guide to [protecting muscle from sarcopenia on GLP-1s](/blog/glp1-menopause-muscle-loss-sarcopenia-protect-guide).

Hormone fluctuations can also overlap with side effects: hot flashes and GLP-1 nausea can compound each other in perimenopause, something we break down in [managing hot flashes and nausea together](/blog/hot-flashes-and-nausea-glp1-menopause-managing-both).

For many women, the combination is worth discussing with a clinician — the evidence suggests they complement each other. HRT treats vasomotor symptoms (hot flashes, night sweats), protects bone density, and appears to enhance GLP-1 weight loss. GLP-1s treat the weight and metabolic side of the midlife equation.

The 2024 Menopause study found no new safety signals from combining them, and the two therapies work through entirely different mechanisms — estrogen receptors versus gut hormone receptors — so there's no known pharmacological conflict. One practical note: oral estrogen absorption could theoretically be affected by slowed gastric emptying from GLP-1s, which is one reason many clinicians prefer transdermal estrogen (patch or gel) for women on GLP-1s.

This is an individual decision that depends on your age, time since menopause, cardiovascular and breast cancer risk profile, and symptom burden. The full picture — who's a candidate, which formulations pair best, and what monitoring looks like — is covered in our complete guide to [combining HRT and GLP-1 therapy](/blog/hrt-and-glp-1-combination-therapy-menopause-weight-loss).

Most menopausal women can expect to lose 10–20% of their starting body weight over 12–18 months, depending on the medication and dose. Semaglutide (Wegovy) averaged 14.9% in STEP 1; tirzepatide (Zepbound) averaged 20.9% at the top dose in SURMOUNT-1, and 20.2% versus 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial (NEJM 2025).

A realistic timeline matters more than a single number. Weight loss is typically fastest in months 2–6 after dose escalation, then slows. Expect plateaus — they're physiology, not failure. Non-scale wins often show up first: quieter food noise, smaller waist circumference (the visceral fat effect), better blood sugar, less joint pain from reduced inflammatory load.

Two expectations to calibrate. First, the scale may move slower than it would have at 35 — sleep disruption and lower muscle mass shave a bit off daily calorie burn. Second, the *composition* of your loss matters more than the speed: prioritize protein (we walk through exact targets in our [protein guide for GLP-1 in menopause](/blog/protein-needs-glp1-menopause-daily-target-grams)) and lift something heavy twice a week so the weight you lose is fat, not muscle and bone.

The two biggest menopause-specific risks are muscle loss and bone loss — both already accelerated by estrogen decline, and both worsened by rapid weight loss of any kind. Studies of GLP-1 weight loss show lean mass can account for a meaningful share of total weight lost if you don't actively defend it. Postmenopausal women also lose bone mineral density fastest in the first years after their final period, and significant weight loss adds to that — a double risk we cover in detail in [bone density on GLP-1s in menopause](/blog/bone-density-glp1-menopause-double-risk-prevention).

The defense plan is consistent across the research: 1.2–1.6 g of protein per kilogram of body weight daily, resistance training 2–3 times weekly, adequate calcium (1,200 mg/day for women over 50) and vitamin D, and a DEXA scan baseline if you have risk factors.

Also watch hydration and gastrointestinal side effects, which can hit harder when layered over perimenopausal symptoms. Most side effects are manageable with dose pacing and food strategy. And if weight loss stalls completely for 8+ weeks, that's a conversation about dose, medication switch, or a deliberate maintenance phase — not a sign the medication 'stopped working because of menopause.'

Start with a clinician who understands both menopause and obesity medicine — ideally one conversation covering hormones, weight, bones, and heart together rather than four separate appointments. Bring your full picture: last period date, current symptoms, family history of breast cancer and heart disease, and any prior DEXA results.

Good questions to ask: Am I a candidate for HRT alongside a GLP-1? Should my estrogen be transdermal given slowed gastric emptying? What's my baseline muscle mass and bone density? What protein target should I hit? Telehealth options have made both GLP-1s and menopause care dramatically more accessible, and costs vary widely — our [GLP-1 savings card guide](/blog/glp1-savings-cards-2026-complete-guide) covers how to cut the medication price.

The bottom line: menopause is not a reason to skip GLP-1 therapy — for many women it's precisely the moment these medications help most, because they counter the exact metabolic shifts estrogen loss creates. With muscle and bone protection in place, the evidence says midlife women do very well on them.